Cargando…
Report of two sisters with Netherton syndrome successfully treated with dupilumab and review of the literature
Different monoclonal antibodies have been used for the treatment of Netherton’s syndrome (NS); secukinumab (anti-IL17A), infliximab (anti-TNF-α), ustekinumab (anti p40 subunit of IL-12 and IL-23), omalizumab (anti-IgE), and dupilumab (anti-IL4 and IL13). We report two sisters with severe NS who were...
Autores principales: | Martin-García, Cristina, Godoy, Elena, Cabrera, Adelaida, Cañueto, Javier, Muñoz-Bellido, Francisco J, Perez-Pazos, Jacqueline, Dávila, Ignacio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10201149/ https://www.ncbi.nlm.nih.gov/pubmed/37200480 http://dx.doi.org/10.1177/03946320231172881 |
Ejemplares similares
-
Dupilumab Improves Pruritus in Netherton Syndrome: A Case Study
por: Inaba, Yutaka, et al.
Publicado: (2022) -
Successful use of secukinumab in Netherton syndrome
por: Blanchard, Sarah K., et al.
Publicado: (2020) -
Dupilumab improves clinical symptoms in children with Netherton syndrome by suppressing Th2-mediated inflammation
por: Yan, Shi, et al.
Publicado: (2022) -
Treatment Experiences with Intravenous Immunoglobulins, Ixekizumab, Dupilumab, and Anakinra in Netherton Syndrome: A Case Series
por: Ragamin, Aviël, et al.
Publicado: (2023) -
Reactive perforating collagenosis successfully treated with dupilumab
por: Gil‐Lianes, Javier, et al.
Publicado: (2022)